Question 1

What is Oculis?

Accepted Answer

Oculis is a Entity.

Question 2

How often does Oculis appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 43 articles.

Question 3

When was Oculis first tracked by Ergen?

Accepted Answer

First tracked on May 29, 2026.

Question 4

When was Oculis last mentioned in news?

Accepted Answer

Last active on Jun 18, 2026.

Question 5

What is Oculis's current news sentiment?

Accepted Answer

Aggregate sentiment score: -80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Oculis in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Oculis?

Accepted Answer

Oculis OCS-01 trial failure, fraud investigation (May 29, 2026, 43 articles).

Question 8

Who is Oculis most connected to?

Accepted Answer

Top relationships: Riad Sherif, Riad Sherif, United States — Food and Drug Administration.

Question 9

How did the "Oculis OCS-01 trial failure, fraud investigation" event impact Oculis?

Accepted Answer

Oculis is the subject of a securities fraud investigation by multiple law firms after its lead drug candidate, OCS-01, failed to meet primary endpoints in late-stage trials, causing a significant drop in its stock price. The company's decision not to pursue an FDA filing for OCS-01 further negatively impacts its market standing.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.